Asunaprevir
Names | |
---|---|
IUPAC name
3-Methyl-N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-valyl-(4R)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-vinylcyclopropyl}-L-prolinamide
| |
Preferred IUPAC name
tert-Butyl {(2S)-1-[(32S,34R,61R,62S)-17-chloro-62-ethenyl-14-methoxy-4,7,9,9-tetraoxo-2-oxa-9λ6-thia-5,8-diaza-1(1)-isoquinolina-3(4,2)-pyrrolidina-6(1,1),10(1)-dicyclopropadecaphan-31-yl]-3,3-dimethyl-1-oxobutan-2-yl}carbamate | |
Other names
BMS-650032
| |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.206.482 |
KEGG | |
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
C35H46ClN5O9S | |
Molar mass | 748.29 g·mol−1 |
Pharmacology | |
J05AP06 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
Infobox references | |
Asunaprevir (formerly BMS-650032, brand name in Japan and Russia[1] Sunvepra) is an experimental drug candidate for the treatment of hepatitis C. It was undergoing development by Bristol-Myers Squibb and has completed Phase III clinical trials in 2013.[2]
Asunaprevir is an inhibitor of the hepatitis C virus enzyme serine protease NS3.[3]
Asunaprevir is being tested in combination with pegylated interferon and ribavirin, as well as in interferon-free regimens with other direct-acting antiviral agents including daclatasvir.[4][5][6]
See also[]
References[]
- ^ "Sunvepra™ (asunaprevir) soft gelatin capsules 100 mg. Registration certificate". State Register of Medicines (in Russian). Retrieved 26 August 2015.
- ^ "A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients". ClinicalTrials.gov.
- ^ C. Reviriego (2012). "Asunaprevir. HCV serine protein NS3 inhibitor, Treatment of hepatitis C virus". Drugs of the Future. 37 (4): 247–254. doi:10.1358/dof.2012.037.04.1789350.
- ^ Lok, A; et al. (2012). "Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1". New England Journal of Medicine. 366 (3): 216–224. doi:10.1056/NEJMoa1104430. PMID 22256805.
- ^ "Bristol-Myers' Daclatasvir, Asunaprevir Cured 77%: Study". Bloomberg. Apr 19, 2012.
- ^ AASLD: Daclatasvir plus Asunaprevir Rapidly Suppresses HCV in Prior Null Responders Archived 2015-02-08 at the Wayback Machine. Highleyman, L. HIVandHepatitis.com. 8 November 2011.
Categories:
- Carbamates
- Chloroarenes
- Cyclopropanes
- Experimental drugs
- Isoquinolines
- NS3/4A protease inhibitors
- Pyrrolidines
- Sulfonamides
- Tert-butyl compounds
- Antiinfective agent stubs